Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?

Lancet Oncol. 2021 Jan;22(1):5-6. doi: 10.1016/S1470-2045(20)30636-7. Epub 2020 Dec 21.

Authors

Rupert Bartsch¹, Christoph Minichsdorfer², Cornelia Kolberg-Liedtke³

Affiliations

¹ Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: [email protected].
² Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
³ Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany.

PMID: 33357419
DOI: 10.1016/S1470-2045(20)30636-7

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Breast Neoplasms* / drug therapy
Breast Neoplasms* / epidemiology
Humans
Injections, Subcutaneous
Trastuzumab

Substances

Antibodies, Monoclonal, Humanized
pertuzumab
Trastuzumab